CoLucid gets $25M

CompanyAmount/RoundLead InvestorsDescription

CoLucid CoLucid Pharmaceuticals
Care Capital

The financing will be used to develop COL-144, a migraine compound, and to advance preclinical pipeline candidates that target neurological and psychiatric disorders.

Immune Design
Alta Partners, The Column Group and Versant Ventures

The vaccine company is developing therapies targeting dendritic cells, which control the human immune response system. And its researchers plan to develop new vaccines as well as enhance existing therapies.

Limerick BioPharma
South San Francisco
Arch Venture Partners, Sevin Rosen Funds and Altitude Funds

Limerick BioPharma will advance its work on the bioavailability of drugs.

CoLucid gets $25M

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.